Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is hoped that this approval is just the beginning of the many drugs yet to be discovered using this fascinating technique.
This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.
"Sinopsis" puede pertenecer a otra edición de este libro.
Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is hoped that this approval is just the beginning of the many drugs yet to be discovered using this fascinating technique.
This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.
Fragment-based drug discovery is a rapidly evolving area of research, which has recently seen new applications in areas such as epigenetics, GPCRs and the identification of novel allosteric binding pockets. The first fragment-derived drug was recently approved for the treatment of melanoma. It is hoped that this approval is just the beginning of the many drugs yet to be discovered using this fascinating technique.
This book is written from a Chemist's perspective and comprehensively assesses the impact of fragment-based drug discovery on a wide variety of areas of medicinal chemistry. It will prove to be an invaluable resource for medicinal chemists working in academia and industry, as well as anyone interested in novel drug discovery techniques.
Personal Essay: Fragments in the Blogosphere Daniel A. Erlanson,
Personal Essay: Adventures and Experiences in Fragment-Based Drug Discovery Martin J. Drysdale,
Chapter 1 Different Flavours of Fragments Chris Abell and Claudio Dagostin,
Chapter 2 Getting the Most Value from Your Screens: Advances in Hardware, Software, and Methodologies to Enhance Surface Plasmon Resonance Based Fragment Screening and Hit-to-Lead Support Anthony M. Giannetti, Houston N. Gilbert, Donald P. Huddler, Mac Reiter, Chris Strande, Keith E. Pitts, and Brandon J. Bravo,
Chapter 3 Applications of NMR in Fragment-Based Drug Design Isabelle Krimm,
Chapter 4 Current Status and Future Direction of Fragment-Based Drug Discovery: A Computational Chemistry Perspective Ian D. Wall, Michael M. Hann, Andrew R. Leach, and Stephen D. Pickett,
Chapter 5 Fragment Screening of G Protein-Coupled Receptors Miles Congreve and Robert Cooke,
Chapter 6 Fragment-Based Lead Discovery Applied to Protein–Protein Interactions Roderick E. Hubbard,
Chapter 7 Fragment-Based Discovery of Allosteric Ligands Steven Howard,
Chapter 8 Fragment-Based Discovery of Antibacterials Christina Spry and Anthony G. Coyne,
Chapter 9 Exploring Fragment Screening and Optimization Strategies Using Acetylcholine-Binding Protein Ewald Edink, Gerdien E. de Kloe, and Iwan J. P. de Esch,
Chapter 10 Fragment-Based Approaches to Epigenetic Targets Chun-wa Chung and Paul Bamborough,
Subject Index,
Different Flavours of Fragments
CHRIS ABELL AND CLAUDIO DAGOSTIN
1.1Fragment-Based Drug Discovery
Fragment-based drug discovery is becoming a powerful technology in the arsenal of the pharmaceutical companies to aid discovery of new small-molecule therapeutics, establish the druggability of biological targets, and discover alternative inhibition sites on already established ones. With the market approval of Zelboraf® (Vemurafenib – the first drug discovered via fragment-based drug discovery) the approach has a measure of validation and interest in the field continues to grow.
Fragments are small molecules that may become parts of a larger molecule, but in some cases were fragments of known drugs, that have been used as starting points to find new inhibitors for different biological targets. A fragment is a small, typically aromatic, organic molecule of molecular weight <250 Da, which is very soluble and chemically stable. The use of such small molecules at the beginning of a medicinal chemistry program allows an effective exploration of chemical space and a more rational design of the final molecule through iterations guided by structural knowledge of the site of binding. In the best cases, the approach can offer a less expensive and faster route to potent and better quality lead compounds compared with more traditional approaches such as high-throughput screening (HTS) of higher molecular weight compounds.
1.2 Different Types of Fragments
Views on the composition of fragment libraries have evolved over time. Some libraries were assembled by taking known drugs and dissecting them into fragments or by computationally finding diverse fragments. It was apparent from the start that solubility would be very important because of the concentrations used for screening (often tens of mM). Another key criterion was lack of reactive groups altho
"Sobre este título" puede pertenecer a otra edición de este libro.
GRATIS gastos de envío en Estados Unidos de America
Destinos, gastos y plazos de envíoLibrería: Basi6 International, Irving, TX, Estados Unidos de America
Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Nº de ref. del artículo: ABEOCT25-222483
Cantidad disponible: 5 disponibles
Librería: Romtrade Corp., STERLING HEIGHTS, MI, Estados Unidos de America
Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Nº de ref. del artículo: ABNR-66914
Cantidad disponible: 1 disponibles
Librería: SMASS Sellers, IRVING, TX, Estados Unidos de America
Condición: New. Brand New Original US Edition. Customer service! Satisfaction Guaranteed. Nº de ref. del artículo: ASNT3-66914
Cantidad disponible: 1 disponibles
Librería: ALLBOOKS1, Direk, SA, Australia
Brand new book. Fast ship. Please provide full street address as we are not able to ship to P O box address. Nº de ref. del artículo: SHAK222483
Cantidad disponible: 5 disponibles
Librería: Books Puddle, New York, NY, Estados Unidos de America
Condición: New. Nº de ref. del artículo: 26372229714
Cantidad disponible: 1 disponibles
Librería: Majestic Books, Hounslow, Reino Unido
Condición: New. Nº de ref. del artículo: 374897037
Cantidad disponible: 1 disponibles
Librería: Biblios, Frankfurt am main, HESSE, Alemania
Condición: New. Nº de ref. del artículo: 18372229720
Cantidad disponible: 1 disponibles
Librería: Romtrade Corp., STERLING HEIGHTS, MI, Estados Unidos de America
Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Nº de ref. del artículo: ABNR-99624
Cantidad disponible: 1 disponibles
Librería: Romtrade Corp., STERLING HEIGHTS, MI, Estados Unidos de America
Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide. Nº de ref. del artículo: ABNR-99356
Cantidad disponible: 1 disponibles
Librería: Basi6 International, Irving, TX, Estados Unidos de America
Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. Nº de ref. del artículo: ABEOCT25-222484
Cantidad disponible: 1 disponibles